아시트레틴(Acitretin) 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Acitretin Market was valued at USD 36.6 million in 2025 and is estimated to grow at a CAGR of 5% to reach USD 59.2 million by 2035.

The market's expansion is fueled by the rising prevalence of psoriasis across multiple regions, supported by better diagnostic tools and shifting population demographics. As more patients are diagnosed earlier, the need for systemic therapies that offer long-term symptom management continues to grow. This trend is particularly prominent in high-income countries where lifetime prevalence rates are increasing, as well as in regions enhancing dermatological infrastructure. The growing global burden of psoriasis directly drives steady, sustained demand for acitretin. Furthermore, heightened awareness about psoriasis and its broader health implications is promoting early diagnosis and timely treatment. International initiatives aimed at educating the public and policymakers are helping reduce stigma and encourage medical consultation, increasing detection rates in both developed and emerging markets. Together, these factors are establishing a strong foundation for the market's long-term growth.

The generic acitretin segment accounted for USD 18.8 million in 2025. Generic products follow strict regulatory standards and must demonstrate bioequivalence to the reference drug, ensuring comparable safety and efficacy. With decades of clinical knowledge, generics do not require extensive repeat trials, making them highly cost-effective and widely accessible. This affordability and availability appeal to clinicians, payers, and patients, particularly in price-sensitive healthcare systems, ensuring broad adoption.

The 25 mg segment reached USD 17.3 million in 2025. This strength allows precise dose titration to optimize efficacy while minimizing side effects. Lower doses improve patient tolerance, reduce adverse effects, and support long-term adherence, which is critical for sustained psoriasis management.

U.S. Acitretin Market reached USD 13.7 million in 2025. High psoriasis prevalence and the need for effective systemic therapies are key growth drivers. Acitretin is particularly important for patients who cannot use biologic treatments due to contraindications, cost, or preference for non-immunosuppressive therapies. The combination of widespread diagnosis, significant disease burden, and ongoing treatment requirements continues to support the U.S. market.

Key companies in the Global Acitretin Market include Biophore, Teva Pharmaceuticals Industries Ltd, Glenmark Pharmaceuticals Ltd, Sun Pharma Industries Limited, GSK Plc, Alembic Pharmaceuticals Ltd, Amneal Pharmaceuticals, Inc., Merck KGaA, Chongqing Huapont Pharmaceutical Co., Ltd., and Prasco Laboratories. Market players are strengthening their presence by expanding generic and branded product portfolios, investing in R&D for improved formulations, and focusing on bioequivalence and safety validation to gain regulatory approval. Companies are pursuing strategic collaborations with distributors and healthcare providers to enhance market penetration and accessibility. Pricing strategies, patient assistance programs, and education initiatives for clinicians and patients are used to drive adoption. Additionally, firms leverage digital platforms to increase awareness of psoriasis management and promote treatment adherence, while investing in emerging markets to capture underserved patient populations and sustain long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Product type trends
  • 2.2.2 Dosage strength trends
  • 2.2.3 Application trends
  • 2.2.4 Distribution channel trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of psoriasis globally
    • 3.2.1.2 Advancements in treatment
    • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.1.4 Growing dermatology specialty clinics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Side effects and safety concerns
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising demand for cost-effective alternatives to biologics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Branded
• 5.3 Generics

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 10 mg
• 6.3 25 mg
• 6.4 50 mg

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Psoriasis
• 7.3 Ichthyosis
• 7.4 Darier disease
• 7.5 Pityriasis rubra pilaris
• 7.6 Solid organ transplants
• 7.7 Grover’s disease
• 7.8 Lichen planus
• 7.9 Lupus erythematosus

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Online pharmacies
• 8.4 Retail pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 1.1.1 U.S.
  • 1.1.2 Canada
• 9.3 Europe
  • 1.1.3 Germany
  • 1.1.4 UK
  • 1.1.5 France
  • 1.1.6 Spain
  • 1.1.7 Italy
  • 1.1.8 Netherlands
• 9.4 Asia Pacific
  • 1.1.9 China
  • 1.1.10 Japan
  • 1.1.11 India
  • 1.1.12 Australia
  • 1.1.13 South Korea
• 9.5 Latin America
  • 1.1.14 Brazil
  • 1.1.15 Mexico
  • 1.1.16 Argentina
• 9.6 Middle East and Africa
  • 1.1.17 South Africa
  • 1.1.18 Saudi Arabia
  • 1.1.19 UAE

Chapter 10 Company Profiles

• 10.1 Amneal Pharmaceuticals, Inc.
• 10.2 Biophore
• 10.3 Chongqing Huapont Pharmaceutical Co., Ltd.
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 GSK Plc
• 10.6 Merck KGaA
• 10.7 Prasco Laboratories
• 10.8 Sun Pharma Industries Limited
• 10.9 Teva Pharmaceuticals Industries Ltd
• 10.10 Alembic Pharmaceuticals Ltd